Sublingual versus oral immunotherapy for peanut-allergic children: A retrospective comparison

• Published in: Journal of allergy and clinical immunology Vol. 132; no. 2; pp. 476 - 478.e2
• Main Authors: Chin, Stacy J., MD, Vickery, Brian P., MD, Kulis, Michael D., PhD, Kim, Edwin H., MD, Varshney, Pooja, MD, Steele, Pamela, CPNP, Kamilaris, Janet, RN, Hiegel, Anne M., RN, Carlisle, Suzanna K., RN, Smith, P. Brian, MD, MPH, MHS, Scurlock, Amy M., MD, Jones, Stacie M., MD, Burks, A. Wesley, MD
• Format: Journal Article
• Language: English
• Published: New York, NY Mosby, Inc 01.08.2013; Elsevier; Elsevier Limited
• Subjects: Administration, Oral; Administration, Sublingual; Allergens - administration & dosage; Allergens - immunology; Allergies; Allergy and Immunology; Arachis - immunology; Biological and medical sciences; Child; Child, Preschool; Desensitization, Immunologic - methods; Female; Food allergies; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Humans; Immunotherapy; Male; Medical sciences; Peanut Hypersensitivity - immunology; Peanut Hypersensitivity - therapy; Retrospective Studies; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis; Studies; Treatment Outcome; Human; Food allergy; Immunopathology; Desensitization; Immunology; Oral administration; Sublingual administration; Digestive diseases; Child; Comparative study; Retrospective
• ISSN: 0091-6749; 1097-6825
• DOI: 10.1016/j.jaci.2013.02.017

To the Editor: There has been considerable recent interest in developing therapies for food allergy, an increasingly common and highly morbid disorder for which strict dietary elimination and ready access to epinephrine remain the standard of care.1 While both oral immunotherapy (OIT)2-4 and sublingual immunotherapy (SLIT)5 have been shown to induce clinical desensitization to foods (reviewed in Narisety and Keet6), no head-to-head comparative analysis of the 2 treatments has been published. Median peanut-specific IgE (kU/L), range 58.5 (12-985) 61.7 (8.5-1636) .67 Median skin prick test (mm), range 14.5 (7-26) 11.5 (3.5-23.5) .04 Asthma, n (%) 13 (57) 14 (52) .78 Atopic dermatitis, n (%) 17 (74) 21 (78) >.99 Allergic rhinitis, n (%) 16 (70) 19 (71) >.99 Other food allergy, n (%) 14 (61) 9 (33) .09 Table I Baseline subject characteristics Dose Interval (min) Individual dose (mg flour)[low *] Cumulative dose (g flour) 1 -- 5 0.0050 2 20 15 0.0200 3 20 50 0.0700 4 20 100 0.1700 5 20 250 0.4200 6 20 500 0.9200 7 20 1000 1.9200 8 20 1500 3.4200 9 20 2000 5.4200 10 20 4000 9.4200 Table E1 Dosing schedule for OIT DBPCFC Dose Interval (min) Individual dose (mg flour)[low *] Cumulative dose (g flour) 1 -- 170 0.170 2 20 250 0.420 3 20 500 0.920 4 20 1000 1.920 5 20 1500 3.420 6 20 1580 5.000 Table E2 Dosing schedule for SLIT DBPCFC